1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. HMG-CoA Reductase (HMGCR)

HMG-CoA Reductase (HMGCR)

HMG-CoA Reductase (HMGCR) is the rate-limiting enzyme for cholesterol synthesis in the conversion of HMG-CoA to mevalonate. HMGCR is found in eukaryotes and prokaryotes. The phylogenetic analysis has revealed two classes of HMG-CoA reductase, the Class I enzymes of eukaryotes and some archaea and the Class II enzymes of eubacteria and certain other archaea.

Both in eukaryotes and in archaebacteria the enzyme HMGCR is known to catalyze an early reaction unique to isoprenoid biosynthesis. In humans, the HMG-CoA reductase reaction is rate-limiting for the biosynthesis of cholesterol and therefore constitutes a prime target of drugs that reduce serum cholesterol levels.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0144AS1
    Pitavastatin-d5 sodium
    Inhibitor 99.53%
    Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
    Pitavastatin-d<sub>5</sub> sodium
  • HY-B0144AS
    Pitavastatin-d4
    Inhibitor 99.09%
    Pitavastatin-d4 is deuterium labeled Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.
    Pitavastatin-d<sub>4</sub>
  • HY-B1189S
    Meglutol-d3
    98.04%
    Meglutol-d3 is the deuterium labeled Meglutol[1]. Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.
    Meglutol-d<sub>3</sub>
  • HY-14664C
    (3S,5R)-Fluvastatin sodium
    Inhibitor 98.16%
    (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer of Fluvastatin. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
    (3S,5R)-Fluvastatin sodium
  • HY-17504S
    Rosuvastatin-d6 calcium
    Inhibitor 98.54%
    Rosuvastatin-d6 (calcium) is deuterium labeled Rosuvastatin.
    Rosuvastatin-d<sub>6</sub> calcium
  • HY-17504BS1
    Rosuvastatin-d6 sodium
    Inhibitor 98.60%
    Rosuvastatin-d6 (sodium) is deuterium labeled Rosuvastatin.
    Rosuvastatin-d<sub>6</sub> sodium
  • HY-B0165
    Pravastatin
    Inhibitor
    Pravastatin (CS-514) is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
    Pravastatin
  • HY-B0589E
    Atorvastatin hemicalcium trihydrate
    Inhibitor
    Atorvastatin hemicalcium trihydrate is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin hemicalcium trihydrate
  • HY-17502S1
    Simvastatin-d3
    Simvastatin-d3 is the deuterium labeled Simvastatin[1]. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM[2].
    Simvastatin-d<sub>3</sub>
  • HY-14664D
    Fluvastatin sodium monohydrate
    Inhibitor
    Fluvastatin (XU 62-320) sodium monohydrate is a first fully synthetic, competitive HMG-CoA reductaseinhibitor with an IC50 of 8 nM. Fluvastatin (sodium monohydrate) protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
    Fluvastatin sodium monohydrate
  • HY-B0144B
    Pitavastatin sodium
    Inhibitor
    Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects.
    Pitavastatin sodium
  • HY-110231
    Simvastatin-d6
    Inhibitor
    Simvastatin-d6 (MK 733-d6) is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    Simvastatin-d6
  • HY-B0589S1
    Atorvastatin-d5 sodium
    Inhibitor
    Atorvastatin-d5 (sodium) is the deuterium labeled Atorvastatin sodium. Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3][4].
    Atorvastatin-d<sub>5</sub> sodium
  • HY-119695B
    Simvastatin acid calcium hydrate
    Inhibitor
    Simvastatin acid (Tenivastatin) calcium hydrate is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid calcium hydrate reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid calcium hydrate can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene.
    Simvastatin acid calcium hydrate
  • HY-B0165S
    Pravastatin-d9 sodium
    Inhibitor
    Pravastatin-d9 sodium is deuterated labeled Pravastatin (HY-B0165). Pravastatin (CS-514) is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
    Pravastatin-d<sub>9</sub> sodium
  • HY-139134
    S-2E
    Inhibitor
    S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research.
    S-2E
  • HY-116241
    L-157012
    Inhibitor
    L-157012 is a HMG-CoA reductase (HMGCR) inhibitor. L-157012 is also a cholesterol-lowering agent.
    L-157012
  • HY-17504AS
    Rosuvastatin-d3
    Inhibitor
    Rosuvastatin-d3 is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].
    Rosuvastatin-d<sub>3</sub>
  • HY-17504C
    (3R,5R)-Rosuvastatin
    Inhibitor
    (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    (3R,5R)-Rosuvastatin
  • HY-N11637
    Ganoderenic acid K
    Inhibitor
    Ganoderenic acid K is a natural product, that can be isolated from fruiting bodies of Ganoderma lucidum. Ganoderenic acid K shows strong inhibitory activity against HMG-CoA reductase (HMGCR) with IC50 of 16.5 μM.
    Ganoderenic acid K
Cat. No. Product Name / Synonyms Application Reactivity